Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Profound Medical (PROF) Liabilities and Shareholders Equity (2023 - 2025)

Profound Medical (PROF) has 3 years of Liabilities and Shareholders Equity data on record, last reported at $77.5 million in Q4 2025.

  • For Q4 2025, Liabilities and Shareholders Equity rose 10.31% year-over-year to $77.5 million; the TTM value through Dec 2025 reached $230.3 million, up 227.92%, while the annual FY2025 figure was $77.5 million, 10.31% up from the prior year.
  • Liabilities and Shareholders Equity reached $77.5 million in Q4 2025 per PROF's latest filing, up from $42.3 million in the prior quarter.
  • Across five years, Liabilities and Shareholders Equity topped out at $77.5 million in Q4 2025 and bottomed at $42.3 million in Q3 2025.
  • Average Liabilities and Shareholders Equity over 3 years is $57.4 million, with a median of $55.3 million recorded in 2025.
  • Peak YoY movement for Liabilities and Shareholders Equity: soared 59.78% in 2024, then grew 10.31% in 2025.
  • A 3-year view of Liabilities and Shareholders Equity shows it stood at $44.0 million in 2023, then skyrocketed by 59.78% to $70.2 million in 2024, then rose by 10.31% to $77.5 million in 2025.
  • Per Business Quant database, its latest 3 readings for Liabilities and Shareholders Equity were $77.5 million in Q4 2025, $42.3 million in Q3 2025, and $49.7 million in Q2 2025.